Clinical Trial Update: ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating tocilizumab (Actemra) for pediatric adamantinomatous craniopharyngioma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adamantinomatous Craniopharyngioma

Drugs mentioned

• Actemra (tocilizumab)

Snippet

Sponsor: Nationwide Children's Hospital | Conditions: Adamantinomatous Craniopharyngioma, Recurrent Adamantinomatous Craniopharyngioma | Phase 2 | Status: RECRUITING